Recent discovery and development of endothelin receptor antagonist

Expert Opinion on Therapeutic Patents

Volumn 10, Issue 11, 2000, Pages 1653-1668

  Wu, C ^a  

^a TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

Balanced; Congestive heart failure; Endothelin; ET(A); ET(B); Pulmonary hypertension; Receptor antagonist; Selective; Selectivity

Indexed keywords

(2ALPHA,3BETA,4ALPHA) 4 (1,3 BENZODIOXOL 5 YL) 1 [2 (2,6 DIETHYLPHENYL)AMINO] 2 OXOETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; 2 [4 (2 ISOPROPOXYETHOXY)PHENYL] 4 (1,3 BENZODIOXOL 5 YL) 1 (BIS 2 TOLYLMETHYLAMINOCARBONYLMETHYL)PYRROLIDINE 3 CARBOXYLIC ACID; 2 [5 (1,3 BENZODIOXOL 5 YLMETHOXY) 2 CYANOPHENOXY] 2 (2 METHYLPHENYL)ACETIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; ABT 546; ACETOPHENONE DERIVATIVE; ATRASENTAN; BIPHENYL DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PD 180988; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; RO 46 8443; SB 247083; SITAXSENTAN; TARASENTAN; TBC 10849; TBC 10894; TBC 10950; TBC 2576; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; Z 1611;

ANIMAL EXPERIMENT; ANIMAL MODEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING; DRUG CLASSIFICATION; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HYPERTENSION; IC 50; NONHUMAN; PATENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PULMONARY HYPERTENSION; RAT; RECEPTOR AFFINITY; REVIEW; STRUCTURE ANALYSIS;

EID: 0033759363     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.10.11.1653     Document Type: Review

References (48)

1. Novel potent vasoconstrictor peptide produced by vascular endothelin cells
2. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
3. Cloning and expression of a cDNA encoding an endothelin receptor
4. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor
5. Cloning and functional expression of human cDNA for the ET(B) endothelin receptor
6. Cloning and expression of human endothelin-1 receptor cDNA
7. Molecular cloning of a non-isopeptide selective human endothelin receptor
8. Update on endothelin
9. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
10. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure
11. Role of endogenous endothelin in chronic heart failure: Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics and cardiac remodeling
12. New targets for heart-failure therapy: Endothelin, inflammatory cytokines and oxidative stress
13. Clinical significance of endothelin in cardiovascular disease
14. Clinical experience with endothelin antagonists
15. Molecular and cellular mechanisms of myocardial failure
16. Endothelin in chronic renal failure
17. Does endothelin-1 play a role in the pathogenesis of cerebral vasospasm?
18. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist
19. Cyclic pentapeptide endothelin antagonists with ET(A) selectivity. Potency and solubility enhancing modifications
20. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist
21. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist
22. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure
23. Endothelin antagonists: Substituted mesitylcarboxamides with high potency and selectivity for ET(A) receptors
24. Discovery of potent, orally available, ET(A) selective endothelin antagonists: TBC3214 and TBC3711
25. The discovery of sulfonamide endothelin antagonists and the development of the orally active ET(A) antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenes ulfonamide
26. Discovery of BMS-193884, a potent and selective ET(A) receptor antagonist
27. Discovery of a novel series of orally active non-peptide endothelin-A (ET(A)) receptor-selective antagonists
28. PD180988, a potent ET(A) selective antagonist and its therapeutic potential
29. 2,4-Diarylpyrrolidine-3-carboxylic acids-potent ET(A) selective endothelin receptor antagonists
30. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ET(A) antagonist (A-216546)
31. Endothelin receptor antagonists
32. Endothelin-1: Cardiovascular physiology, pharmacology and a putative role in the pathogenesis of pulmonary hypertension
33. Selective ET(A) antagonists. 5. Discovery and structure-activity relationships of phenoxyphenylacetic acid derivatives
34. 1,3-Disubstituted-2-carboxy quinolones: Highly potent and selective endothelin A receptor antagonists
35. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist BQ-788
36. In vitro characterisation of Ro 46-8443, the first non-peptide antagonist selective for the endothelin ET-B receptor
37. The discovery and structure-activity relationshiops of nonpeptide, low molecular weight antagonists selective for the endothelin ET(B) receptor
38. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity
39. Design, synthesis and activity of a series of pyrrolidine-3-carboxylic acid-based, highly specific, orally active ET(B) antagonists containing a diphenylmethylamine acetamide side chain
40. Pharmacological characterization of bosentan, a new potent orally active non-peptide endothelin receptor antagonist
41. Preclinical and clinical pharmacology of tezosentan, a new endothelin receptor antagonist designed for parenteral use
42. 1,3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonists
43. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB217242, a potent and highly bioavailable endothelin receptor antagonist
44. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ET(A)/ET(B) mixed antagonists
45. Discovery and synthesis of (S)-3-[2-(3,4-dimethoxy phenyl)ethoxy]-2-(4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 302872), a novel orally active mixed ET(A)/ET(B) receptor antagonist
46. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ET(A)/ET(B) endothelin receptor antagonist
47. A new endothelin receptor antagonist, TAK-044, shows long-lasting inhibition of both ET(A)- and ET(B)-mediated blood pressure responses in rats